Short answer: Compounded omeprazole oral suspension is prepared when a paediatric patient requires a liquid formulation at a strength or volume no commercially available product offers — infants and small children who cannot swallow capsules need a precise, palatable liquid dose individualised to weight. A compounding pharmacy prepares it on a doctor’s prescription under Good Compounding Practice (GCP), as a non-sterile oral liquid for a named patient.
Why omeprazole suspension matters in paediatric practice
Omeprazole, a proton-pump inhibitor (PPI), is established in paediatric gastro-oesophageal reflux disease (GORD). A multicentre study of omeprazole in children with chronic erosive oesophagitis demonstrated efficacy, safety and tolerability across paediatric age groups, with dose requirements individualised to the patient (Hassall et al., The Journal of Pediatrics, 2000; PMID 11113836). A Cochrane systematic review of pharmacological treatment of gastro-oesophageal reflux in children examined the evidence base for PPIs and other agents in this population (Tighe et al., Cochrane Database of Systematic Reviews, 2023; PMID 37635269).
The pharmaceutical problem is straightforward: omeprazole is commercially available in Malaysia as enteric-coated capsules and tablets, but not as a registered paediatric oral liquid. When a prescriber needs a liquid dose for an infant or a child who cannot swallow a capsule, the options are to open the capsule and disperse the contents — which is unreliable and unpalatable — or to compound a suspension from the active to a specified concentration.
The formulation challenge: stability and palatability
Omeprazole is acid-labile. In an oral liquid vehicle, it degrades unless protected from gastric acid and unless the vehicle maintains an appropriate pH. A compounded omeprazole suspension is typically prepared using a bicarbonate-based vehicle that protects the active during passage through the stomach, with the suspension administered on an empty stomach to optimise the protective effect.
Palatability is a second, equally important consideration. A 2026 comparative sensory evaluation of paediatric liquid omeprazole formulations available in the UK examined taste and acceptability differences across preparations, highlighting that formulation vehicle and flavouring significantly influence how children perceive and tolerate the medicine (Ranmal et al., Clinical Drug Investigation, 2026; PMID 41927994). A clinical study of children’s perceptions about medicines found that taste is a primary driver of whether a child accepts or refuses a medication, and that individual differences in taste sensitivity are substantial (Mennella et al., BMC Pediatrics, 2015; PMID 26391354).
For a compounding pharmacy, these findings translate into practical formulation decisions: the choice of suspending vehicle, the pH of the preparation, the flavouring system, and the beyond-use dating all determine whether the preparation remains stable and whether the child will actually take it.
Dosing considerations for prescribers
Paediatric omeprazole dosing is weight-based, and the exact dose a child needs frequently falls between the strengths of commercially available capsule sizes. A phase I/III study of oral esomeprazole — the S-enantiomer of omeprazole — in Japanese paediatric patients with gastric acid-related disease evaluated pharmacokinetics, safety and efficacy across age groups from infants to adolescents, confirming that dose individualisation is central to paediatric PPI therapy (Shimizu et al., Pediatrics International, 2019; PMID 30422368).
When a prescriber determines that a child needs a specific omeprazole dose — for example, 2 mg per dose for a 4 kg infant — a compounded suspension at a defined concentration (commonly 2 mg/mL) allows accurate dosing by volume using an oral syringe. This is the core compounding rationale: the dose exists in the prescription, but not on a shelf.
What a prescriber specifies
A compounding prescription for omeprazole suspension typically includes:
- Active ingredient and concentration (e.g., omeprazole 2 mg/mL)
- Dosage form: oral liquid (suspension)
- Vehicle preference (e.g., sodium bicarbonate-based suspending vehicle)
- Flavouring preference, where the child’s taste acceptance is a concern
- Beyond-use dating guidance, based on stability data for the chosen vehicle
- Named patient and prescriber details
Practical considerations for Malaysian clinics
In Kuala Lumpur and the Klang Valley, paediatricians and GPs managing infant reflux may find that the commercial omeprazole products available are designed for adults, with no registered paediatric liquid formulation. A compounded suspension bridges this gap — but it is a prescription-only preparation, made for one named patient, not a stock product.
Prescribers should counsel parents on storage (refrigeration may be required depending on the vehicle), shaking before each dose, and the importance of administering on an empty stomach. The beyond-use date assigned by the pharmacy reflects the stability of omeprazole in the specific vehicle used, and parents should be advised not to use the preparation beyond that date.
Discussing an omeprazole suspension preparation with Lynnity
Lynnity prepares compounded omeprazole as a non-sterile oral liquid (suspension) for a named paediatric patient on a doctor’s prescription, under Good Compounding Practice (GCP). The prescriber specifies the concentration, vehicle and flavouring; the pharmacy prepares to that specification. Where a child in the same family requires a different GI preparation — for example, a compounded zinc-L-carnosine capsule or oral liquid for mucosal support — the same prescription channel applies, and the pharmacy can prepare both preparations against the same referral. Clinicians can include the formulation brief — vehicle preference, flavouring, excipient exclusions — alongside the prescription, so the pharmacy can assess compatibility and stability before preparation.
Frequently asked questions
Can omeprazole suspension be prepared at any concentration?
The concentration is specified by the prescriber and prepared by the pharmacy. Common concentrations include 2 mg/mL, but the exact strength depends on the child’s weight-based dose and the volume that is practical to administer. The pharmacy assesses stability of the chosen concentration in the selected vehicle before preparation.
How long does a compounded omeprazole suspension remain stable?
Beyond-use dating depends on the vehicle, concentration and storage conditions. The pharmacy assigns a beyond-use date based on stability data for the specific formulation. Refrigeration may extend the beyond-use period, and parents should follow the pharmacy’s storage instructions and discard the preparation after the assigned date.
Is a compounded omeprazole suspension a registered medicine?
No. A compounded preparation is made to a prescription for one named patient and is not a registered, mass-manufactured product. It is prepared under Good Compounding Practice (GCP) and requires a doctor’s prescription. It is not available for direct purchase.
What flavouring options are available for children who refuse unflavoured medicine?
The prescriber can specify a flavouring preference on the prescription, and the pharmacy incorporates it into the suspension vehicle where compatible. Research on children’s taste perceptions indicates that flavour choice materially affects whether a child accepts an oral liquid, so specifying a flavour the child is known to tolerate is a practical step.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632)
To discuss a patient-specific omeprazole suspension for a child who cannot swallow capsules, consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.